
Nicolas Dulphy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2990592/publications.pdf Version: 2024-02-01



Νιζοιλέ ΠΗΙΡΗΥ

#	Article	IF	CITATIONS
1	Innate lymphoid cells: NK and cytotoxic ILC3 subsets infiltrate metastatic breast cancer lymph nodes. Oncolmmunology, 2022, 11, 2057396.	4.6	9
2	Challenges for NK cell-based therapies: What can we learn from lymph nodes?. , 2021, , 33-51.		0
3	Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease. Leukemia, 2021, 35, 2720-2724.	7.2	29
4	High-dimensional mass cytometry analysis of NK cell alterations in AML identifies a subgroup with adverse clinical outcome. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	29
5	Hematologic disorder–associated <i>Cxcr4</i> gain-of-function mutation leads to uncontrolled extrafollicular immune response. Blood, 2021, 137, 3050-3063.	1.4	13
6	Prevalence of UBA1 mutations in MDS/CMML patients with systemic inflammatory and auto-immune disease. Leukemia, 2021, 35, 2731-2733.	7.2	27
7	MDS/CMML with <i>TET2</i> or <i>IDH</i> mutation Are Associated with Systemic Inflammatory and Autoimmune Diseases (SIAD) and T Cell Dysregulation. Blood, 2020, 136, 31-32.	1.4	3
8	NKG2D/NKG2-Ligand Pathway Offers New Opportunities in Cancer Treatment. Frontiers in Immunology, 2019, 10, 661.	4.8	65
9	CD16+NKG2Ahigh Natural Killer Cells Infiltrate Breast Cancer–Draining Lymph Nodes. Cancer Immunology Research, 2019, 7, 208-218.	3.4	32
10	AHR: leukemic countermeasure against NK cells. Blood, 2018, 132, 1733-1734.	1.4	1
11	Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Haematologica, 2017, 102, 1368-1377.	3.5	114
12	Molecular and Functional Characterization of Lymphoid Progenitor Subsets Reveals a Bipartite Architecture of Human Lymphopoiesis. Immunity, 2017, 47, 680-696.e8.	14.3	33
13	Expression of CD94 byex vivo-differentiated NK cells correlates with thein vitroandin vivoacquisition of cytotoxic features. Oncolmmunology, 2017, 6, e1346763.	4.6	4
14	Patient's Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers. Frontiers in Immunology, 2017, 8, 683.	4.8	10
15	Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial. Blood, 2017, 130, 889-889.	1.4	25
16	Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells. Frontiers in Immunology, 2016, 7, 94.	4.8	26
17	Natural killer cell licensing after double cord blood transplantation is driven by the self-HLA class I molecules from the dominant cord blood. Haematologica, 2016, 101, e209-e212.	3.5	4
18	ldentification of CD245 as myosin 18A, a receptor for surfactant A: A novel pathway for activating human NK lymphocytes. Oncolmmunology, 2016, 5, e1127493.	4.6	15

NICOLAS DULPHY

#	Article	IF	CITATIONS
19	Natural Killer Lymphocytes Are Dysfunctional in Kidney Transplant Recipients on Diagnosis of Cancer. Transplantation, 2015, 99, 2422-2430.	1.0	16
20	Phenotypic analysis of T cells infiltrating colon cancers: Correlations with oncogenetic status. Oncolmmunology, 2015, 4, e1016698.	4.6	14
21	Defective NK Cells in Acute Myeloid Leukemia Patients at Diagnosis Are Associated with Blast Transcriptional Signatures of Immune Evasion. Journal of Immunology, 2015, 195, 2580-2590.	0.8	68
22	Polymorphisms in oxidative stress-related genes are associated with nasopharyngeal carcinoma susceptibility. Immunobiology, 2015, 220, 20-25.	1.9	8
23	Natural Killer Lymphocytes Are Dysfunctional in Kidney Transplant Recipients On Diagnosis of Cancer Transplantation, 2014, 98, 876.	1.0	0
24	Contribution of <scp>CD</scp> 39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis. British Journal of Haematology, 2014, 165, 722-725.	2.5	26
25	Acute myeloid leukemia impairs natural killer cells through the formation of a deficient cytotoxic immunological synapse. European Journal of Immunology, 2014, 44, 3068-3080.	2.9	49
26	Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. Haematologica, 2014, 99, 1860-1867.	3.5	53
27	Soluble MICA-NKG2D interaction upregulates IFN-γ production by activated CD3â^'CD56+ NK cells: Potential impact on chronic graft versus host disease. Human Immunology, 2013, 74, 1536-1541.	2.4	10
28	Natural Killer Cell Function, an Important Target for Infection and Tumor Protection, Is Impaired in Type 2 Diabetes. PLoS ONE, 2013, 8, e62418.	2.5	103
29	At diagnosis, diffuse large <scp>B</scp> ell lymphoma patients show impaired rituximabâ€mediated <scp>NK</scp> ell cytotoxicity. European Journal of Immunology, 2013, 43, 1383-1388.	2.9	19
30	Activation of the Receptor NKG2D Leads to Production of Th17 Cytokines in CD4+ T Cells of Patients With Crohn's Disease. Gastroenterology, 2011, 141, 217-226.e2.	1.3	54
31	NKG2D Activation Drives TH17 Response in Crohn's Disease. Gastroenterology, 2011, 140, S-487-S-488.	1.3	0
32	NK-cell education is shaped by donor HLA genotype after unrelated allogeneic hematopoietic stem cell transplantation. Blood, 2011, 117, 1021-1029.	1.4	67
33	Overexpression of proinflammatory TLR-2-signalling lipoproteins in hypervirulent mycobacterial variants. Cellular Microbiology, 2011, 13, 692-704.	2.1	66
34	M1793 TH17 Cells in Crohn's Disease Express an Innate Immune Receptor: the Natural Killer Activating Receptor 2d. Gastroenterology, 2010, 138, S-420.	1.3	0
35	Oxidative Stress Mediates a Reduced Expression of the Activating Receptor NKG2D in NK Cells from End-Stage Renal Disease Patients. Journal of Immunology, 2009, 182, 1696-1705.	0.8	53
36	NKG2D Ligands Expression and NKG2D-Mediated NK Activity in Sezary Patients. Journal of Investigative Dermatology, 2009, 129, 359-364.	0.7	16

NICOLAS DULPHY

#	Article	IF	CITATIONS
37	MICA-129 genotype, soluble MICA, and anti-MICA antibodies as biomarkers of chronic graft-versus-host disease. Blood, 2009, 114, 5216-5224.	1.4	94
38	An Unusual CD56brightCD16low NK Cell Subset Dominates the Early Posttransplant Period following HLA-Matched Hematopoietic Stem Cell Transplantation. Journal of Immunology, 2008, 181, 2227-2237.	0.8	133
39	Modulation of CD103 Expression on Human Colon Carcinoma-Specific CTL. Journal of Immunology, 2007, 178, 2908-2915.	0.8	45
40	CD4+NKG2D+ T Cells in Crohn's Disease Mediate Inflammatory and Cytotoxic Responses Through MICA Interactions. Gastroenterology, 2007, 132, 2346-2358.	1.3	190
41	Intermediate maturation of Mycobacterium tuberculosis LAM-activated human dendritic cells. Cellular Microbiology, 2007, 9, 1412-1425.	2.1	40
42	Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplantation, 2006, 38, 437-444.	2.4	110
43	BCR/ABL Oncogene Directly Controls MHC Class I Chain-Related Molecule A Expression in Chronic Myelogenous Leukemia. Journal of Immunology, 2006, 176, 5108-5116.	0.8	126
44	Association of HLA-E Polymorphism with Severe Bacterial Infection and Early Transplant-Related Mortality in Matched Unrelated Bone Marrow Transplantation. Transplantation, 2005, 80, 140-144.	1.0	47
45	Early-Onset Ankylosing Spondylitis Is Associated With a Functional MICA Polymorphism. Human Immunology, 2005, 66, 1057-1061.	2.4	66
46	BCR/ABL Oncogene Controls MICA Translation Blood, 2005, 106, 4389-4389.	1.4	6
47	Generation of CD1 tetramers as a tool to monitor glycolipid–specific T cells. Philosophical Transactions of the Royal Society B: Biological Sciences, 2003, 358, 875-877.	4.0	12
48	Efficient priming of antigen-specific cytotoxic T lymphocytes by human cord blood dendritic cells. International Immunology, 2003, 15, 1265-1273.	4.0	42
49	Mature CD8+ T lymphocyte response to viral infection during fetal life. Journal of Clinical Investigation, 2003, 111, 1747-1755.	8.2	140
50	Mature CD8+ T lymphocyte response to viral infection during fetal life. Journal of Clinical Investigation, 2003, 111, 1747-1755.	8.2	206
51	Functional modulation of expanded CD8+ synovial fluid T cells by NK cell receptor expression in HLAâ€B27â€associated reactive arthritis. International Immunology, 2002, 14, 471-479.	4.0	26
52	Vα24-JαQ-Independent, CD1d-Restricted Recognition of α-Galactosylceramide by Human CD4+ and CD8αβ+ T Lymphocytes. Journal of Immunology, 2002, 168, 5514-5520.	0.8	142
53	Immunotherapy of colorectal cancer. British Medical Bulletin, 2002, 64, 181-200.	6.9	11
54	Conserved TCR Î ² chain usage in reactive arthritis; evidence for selection by a putative HLA-B27-associated autoantigen. Tissue Antigens, 2002, 60, 299-308.	1.0	60

NICOLAS DULPHY

#	Article	IF	CITATIONS
55	Heart-directed Autoimmunity: the Case of Rheumatic Fever. Journal of Autoimmunity, 2001, 16, 363-367.	6.5	42
56	Genomic diversity of natural killer cell receptor genes in three populations. Tissue Antigens, 2001, 57, 358-362.	1.0	158
57	A new HLA-B*27 allele (B*2719) identified in a Lebanese patient affected with ankylosing spondylitis. Tissue Antigens, 2001, 58, 30-33.	1.0	18
58	Molecular evidence for antigen-driven immune responses in cardiac lesions of rheumatic heart disease patients. International Immunology, 2000, 12, 1063-1074.	4.0	68
59	Frequent enrichment for CD8 T cells reactive against common herpes viruses in chronic inflammatory lesions: towards a reassessment of the physiopathological significance of T cell clonal expansions found in autoimmune inflammatory processes. European Journal of Immunology, 1999, 29, 973-985.	2.9	130
60	The Umbilical Cord Blood αβ T-Cell Repertoire: Characteristics of a Polyclonal and Naive but Completely Formed Repertoire. Blood, 1998, 91, 340-346.	1.4	160
61	The Umbilical Cord Blood αβ T-Cell Repertoire: Characteristics of a Polyclonal and Naive but Completely Formed Repertoire. Blood, 1998, 91, 340-346.	1.4	8
62	HLA-B * 2707 peptide motif: Tyr C-terminal anchor is not shared by all disease-associated subtypes. Immunogenetics, 1997, 47, 103-105.	2.4	32
63	Differences in endogenous peptides presented by HLA-B*2705 and B*2703 allelic variants. Implications for susceptibility to spondylarthropathies Journal of Clinical Investigation, 1996, 98, 2764-2770.	8.2	59
64	Multi-step defect in NK cells and acute myeloid leukemia interaction. Frontiers in Immunology, 0, 4, .	4.8	0